BMS Collaborated with Immatics to Develop Allogeneic Cell Therapy Programs
Shots:
- Immatics to receive $60M up front & additional fees for certain activities, ~$700M in development, regulatory & commercial milestones along with royalty. Both companies get an option to develop ~4 additional programs
- The collaboration will use Immatics’ gamma delta T cell-derived ACTallo platform with BMS’ expertise to develop allogeneic TCR-T/CAR-T programs. Immatics will lead the preclinical development of the 2 initial programs & BMS will lead the clinical development & commercialization activities of all BMS-owned programs
- Additionally, BMA expands its 2019 agreement with Immatics for autologous TCR-T with 1 additional TCR target where Immatics will receive $20M up front & milestones along with royalties
Ref: Businesswire | Image: BMS
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
